Acetylcholine is a small organic molecule that acts as a neurotransmitter in animals. Released by particular neurons, it carries signals across synapses and changes the activity of other neurons, muscle fibers, and glandular cells. It is the transmitter used at the junctions between motor nerves and skeletal muscles, at several major relay points of the autonomic nervous system, and in distributed networks of the brain. Acetylcholine also occurs in non-neuronal cells, where it can participate in local signaling.
Its effects depend on the receptor and tissue involved. The same substance can initiate skeletal muscle contraction, slow the heart, stimulate secretion, or alter the processing of sensory information. These different outcomes arise principally from two receptor families: nicotinic receptors, which are ion channels, and muscarinic receptors, which act through intracellular signaling pathways. The synthesis, release, detection, and rapid destruction of acetylcholine provide a particularly well-studied example of chemical communication between cells.
Acetylcholine occupied a central place in establishing that nerves communicate chemically rather than exclusively through direct electrical continuity. Research on its actions helped define receptor pharmacology, synaptic vesicle release, and the molecular basis of neuromuscular transmission. Its signaling system is also important in disorders such as myasthenia gravis and Alzheimer’s disease, and it is a target of medicines, natural toxins, and pesticides.
Chemical identity and biological availability
Acetylcholine is the acetate ester of choline. Its structure consists of an acetyl group linked through an ester bond to a two-carbon chain terminating in a quaternary ammonium group. The acetylcholine cation has the molecular formula and a relative molecular mass of approximately 146.21. Laboratory and pharmaceutical preparations commonly contain acetylcholine chloride, whose molar mass is approximately . Distinguishing the cation from its salt matters when reporting concentrations or preparing solutions.
The quaternary nitrogen bears a permanent positive electric charge. Unlike an amine that becomes uncharged when it loses a proton, acetylcholine remains cationic throughout the normal physiological pH range. Its charge and affinity for water strongly limit passive passage through the lipid interior of a cell membrane. Acetylcholine therefore does not readily cross the blood–brain barrier. Central and peripheral acetylcholine pools are produced locally rather than supplied by unrestricted movement of the transmitter from blood into nervous tissue.
The ester linkage is susceptible to hydrolysis, yielding choline and acetate. Although chemical hydrolysis can occur in solution, biological inactivation is dominated by highly efficient enzymes. This instability, together with poor penetration of membranes and the widespread distribution of its receptors, makes acetylcholine itself unsuitable for producing selective, sustained systemic effects. Many substances used to modify cholinergic signaling instead resist enzymatic destruction, alter receptor activation, or change the lifetime of locally released transmitter.
The adjective cholinergic describes cells, fibers, receptors, and processes associated with acetylcholine signaling. A cholinergic neuron is generally identified by its capacity to synthesize and package acetylcholine, particularly through expression of choline acetyltransferase and the vesicular acetylcholine transporter. Choline alone is not an equally specific marker: it is also a component of phospholipids and participates in other branches of metabolism. Likewise, finding acetylcholine in a tissue does not by itself demonstrate a conventional neuronal synapse, because epithelial cells, immune cells, and other non-neuronal populations may also produce it.
Acetylcholine’s molecular structure is small, but receptor recognition is highly selective. The positively charged head group interacts with binding pockets containing aromatic amino acids, while the ester-containing portion contributes additional contacts and geometrical constraints. These interactions illustrate how a compact signaling molecule can activate structurally different receptor families without determining the ultimate physiological response by its chemical identity alone.
Synthesis, vesicular release, and signal termination
Acetylcholine is synthesized in the cytoplasm from choline and acetyl coenzyme A. The reaction is catalyzed by choline acetyltransferase, commonly abbreviated ChAT:
Acetyl coenzyme A connects transmitter production to intermediary metabolism, whereas choline is obtained through uptake from the extracellular environment and from phospholipid metabolism. At many cholinergic nerve terminals, high-affinity, sodium-dependent choline uptake is an important constraint on sustained transmitter synthesis. Choline recovered after acetylcholine breakdown can consequently be reused.
Newly synthesized acetylcholine is concentrated inside synaptic vesicles by the vesicular acetylcholine transporter, VAChT. A vesicular proton pump consumes ATP to establish a proton electrochemical gradient; VAChT uses this stored energy to exchange luminal protons for cytoplasmic acetylcholine. The ChAT and VAChT genes have an unusual genomic arrangement in mammals: the VAChT coding sequence lies within the first intron of the ChAT gene. This arrangement is associated with coordinated expression of two central components of the cholinergic phenotype.
When an action potential reaches a nerve terminal, depolarization opens voltage-gated calcium channels. Calcium entry promotes the fusion of transmitter-containing vesicles with the presynaptic membrane through the vesicular release machinery. Acetylcholine then diffuses to accessible receptors. At some junctions, this is a tightly localized signal across a narrow cleft; elsewhere, transmitter released from axonal swellings influences several nearby cells. Release occurs in discrete packets, or quanta, corresponding approximately to the contents of individual vesicles. Small spontaneous release events occur even without an arriving action potential.
Termination differs from that of transmitters whose principal route of clearance is uptake of the intact molecule. Acetylcholinesterase rapidly cleaves acetylcholine into acetate and choline. This enzyme is concentrated at sites such as the neuromuscular junction, where it prevents persistent activation and preserves the timing of successive signals. Its catalytic efficiency can approach the diffusion-limited range under favorable conditions. Butyrylcholinesterase, a related enzyme present in plasma and other tissues, can also hydrolyze acetylcholine and numerous other esters, although its distribution and physiological roles differ.
The complete signaling cycle therefore depends on several separable processes: precursor uptake, synthesis, vesicle loading, calcium-dependent release, receptor activation, and enzymatic clearance. Blocking any one of these can produce a distinctive physiological effect. Inhibiting synthesis or release reduces cholinergic transmission, whereas inhibiting acetylcholinesterase initially increases receptor exposure to acetylcholine. Excessive or prolonged exposure can subsequently impair signaling through receptor desensitization or sustained membrane depolarization.
Nicotinic and muscarinic receptors
Acetylcholine acts through two major receptor families named for natural compounds that helped distinguish their pharmacology. Nicotinic acetylcholine receptors respond to nicotine, whereas muscarinic acetylcholine receptors respond to muscarine, a compound found in certain mushrooms. These names identify receptor classes rather than normal physiological transmitters: acetylcholine is the endogenous signaling molecule for both families.
Nicotinic receptors are pentameric ion channels. Five protein subunits surround a central pore, and binding of acetylcholine at extracellular interfaces favors channel opening. The resulting current is carried principally by cations, including sodium and potassium; calcium permeability varies substantially with receptor subtype. At the resting membrane potential of most target cells, activation usually produces a net inward current and depolarization. This direct coupling between ligand binding and channel opening permits responses on a millisecond timescale.
The adult skeletal-muscle receptor typically contains two subunits and one each of , , and . In fetal muscle, a subunit occupies the position later taken by . Neuronal nicotinic receptors have different compositions: -containing receptors are prominent in the brain, -containing receptors are important in autonomic ganglia, and subunits can assemble into homopentameric receptors. Subunit composition influences ligand sensitivity, calcium permeability, channel kinetics, and desensitization. Consequently, “nicotinic action” does not describe a single uniform response.
Muscarinic receptors belong to the G protein-coupled receptor family and have seven membrane-spanning helices. Five subtypes, M1 through M5, are recognized. M1, M3, and M5 preferentially couple to G proteins of the family, activating phospholipase C and pathways involving inositol trisphosphate, diacylglycerol, and intracellular calcium. M2 and M4 preferentially couple to , commonly reducing adenylyl cyclase activity. Released G-protein subunits can also regulate ion channels directly, including potassium channels involved in slowing cardiac pacemaker activity.
Receptor family alone does not fully predict the response of a tissue. Muscarinic effects depend on which signaling proteins and channels the target cell expresses; nicotinic effects depend on subunit composition, membrane voltage, and prior exposure. Receptors may also occur presynaptically, where they regulate further transmitter release. M2 and M4 receptors often act as inhibitory autoreceptors on cholinergic terminals. Both receptor families undergo regulation through changes in activation state, trafficking, and abundance, allowing cholinergic responsiveness to vary over timescales from milliseconds to days.
Transmission at the neuromuscular junction
At the vertebrate skeletal neuromuscular junction, acetylcholine converts a motor neuron’s electrical activity into excitation of a muscle fiber. The presynaptic terminal faces a specialized postsynaptic region called the motor end plate. Junctional folds enlarge the postsynaptic membrane, with nicotinic receptors concentrated near the fold crests and voltage-gated sodium channels enriched in deeper regions and adjacent membrane. Acetylcholinesterase associated with the synaptic basal lamina rapidly removes transmitter after release.
A motor nerve action potential triggers the near-synchronous release of many acetylcholine-containing vesicles. Acetylcholine binds muscle nicotinic receptors, opening their channels and generating an end-plate potential. If this local depolarization reaches threshold, voltage-gated sodium channels initiate a muscle action potential. The action potential propagates along the surface membrane and transverse tubules, activating the coupling machinery that releases calcium from the sarcoplasmic reticulum. Calcium then binds the contractile regulatory system, permitting actin–myosin interactions. Acetylcholine thus initiates contraction indirectly; it does not itself bind the contractile proteins.
Normal adult neuromuscular transmission has a substantial safety margin. The end-plate potential usually exceeds the depolarization required to trigger a muscle action potential, so moderate variation in transmitter release does not necessarily cause failure. This margin can shrink when receptor numbers decline, nerve-terminal calcium entry is impaired, or vesicle release is blocked. The relationship between quantal release and postsynaptic responsiveness is therefore crucial to understanding muscle weakness.
Myasthenia gravis is an autoimmune disorder of neuromuscular transmission. In many affected people, autoantibodies target muscle acetylcholine receptors; in other forms, antibodies target proteins such as muscle-specific kinase that organize or maintain the postsynaptic apparatus. Receptor loss, structural disruption, and, in acetylcholine-receptor antibody-positive disease, complement-mediated injury reduce the reliability of transmission. By contrast, Lambert–Eaton myasthenic syndrome primarily affects presynaptic voltage-gated calcium channels and reduces acetylcholine release. Congenital myasthenic syndromes arise from inherited defects in various presynaptic, synaptic, or postsynaptic components rather than from the same autoimmune mechanism.
Toxins and medicines provide additional demonstrations of the junction’s organization. Botulinum toxins cleave proteins required for vesicle fusion and thereby inhibit acetylcholine release. Nondepolarizing neuromuscular blockers occupy muscle nicotinic receptors without producing normal activation. Succinylcholine instead activates the receptors and produces sustained depolarization followed by transmission failure. These mechanisms are distinct despite their shared ability to reduce muscle contraction. They also show why acetylcholine signaling requires brief, appropriately timed receptor activation rather than simply a large amount of transmitter.
Autonomic and visceral functions
Acetylcholine occupies several different positions in the autonomic nervous system. Preganglionic neurons of both its sympathetic and parasympathetic divisions release acetylcholine onto nicotinic receptors in autonomic ganglia. Preganglionic sympathetic fibers also activate nicotinic receptors on adrenal medullary chromaffin cells, promoting the secretion of catecholamines into the circulation. Thus, acetylcholine participates in sympathetic activation even though most sympathetic postganglionic neurons release noradrenaline rather than acetylcholine.
Most postganglionic neurons of the parasympathetic nervous system release acetylcholine onto muscarinic receptors in target organs. Cardiac M2 receptors slow pacemaker activity in the sinoatrial node and reduce conduction through the atrioventricular node. Their signaling lowers cyclic AMP-dependent activity and opens G-protein-regulated potassium channels, helping make pacemaker cells less likely to reach threshold rapidly. These actions chiefly regulate cardiac timing and conduction; their distribution and magnitude differ among cardiac regions.
In glands and many smooth muscles, M3-mediated signaling raises intracellular calcium. Depending on the organ, this promotes salivary and lacrimal secretion, bronchial smooth-muscle contraction, gastrointestinal motility, or urinary bladder detrusor contraction. In the eye, muscarinic activation contracts the pupillary sphincter and ciliary muscle, producing pupillary constriction and changing lens accommodation. Organ-level responses are shaped by local circuits, background activity, receptor distribution, and interactions with other transmitters, rather than by a single undifferentiated “rest-and-digest” command.
An important exception to the usual postganglionic sympathetic pattern is the cholinergic innervation of eccrine sweat glands. These fibers belong anatomically to the sympathetic nervous system, but release acetylcholine that acts mainly through muscarinic receptors. Acetylcholine also participates in enteric circuits within the gastrointestinal tract. There it functions among several transmitters in networks that can coordinate activity locally while remaining subject to extrinsic autonomic influence.
Blood vessels illustrate the importance of separating a drug response from normal innervation. Acetylcholine applied to an intact vascular endothelium can activate muscarinic receptors and promote nitric oxide formation. Nitric oxide diffuses to vascular smooth muscle, where it stimulates cyclic GMP signaling and relaxation. This endothelium-dependent response was central to identifying nitric oxide as a biological messenger. Nevertheless, most systemic blood vessels do not receive dense parasympathetic cholinergic innervation. The capacity of experimentally administered acetylcholine to dilate a vessel does not establish that acetylcholine normally controls that vessel through a direct parasympathetic supply.
Cholinergic systems in the brain
Cholinergic neurons constitute a relatively small fraction of brain neurons, but several populations influence extensive networks. The basal forebrain contains cholinergic groups that project to the cerebral cortex, amygdala, and hippocampus. These include neurons in the medial septum, diagonal band, and nucleus basalis region. In the brainstem, cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei project to thalamic and other targets. The striatum contains a different arrangement: widely branching cholinergic interneurons act within local circuits rather than serving mainly as long-range projection cells.
Acetylcholine helps regulate attention, sensory processing, learning, and behavioral state. These functions cannot be reduced to a simple increase or decrease in overall brain activity. In cortical circuits, cholinergic signaling can change the relative influence of incoming sensory signals, recurrent connections, and inhibitory interneurons. Nicotinic receptors may rapidly influence particular presynaptic terminals or interneuron classes, while muscarinic receptors alter membrane excitability and synaptic responses over longer intervals. The outcome depends on receptor location and on the activity of the surrounding network.
In hippocampal circuits, acetylcholine influences excitability, rhythmic coordination, and conditions for synaptic plasticity. Cholinergic activity has often been associated with states favorable to encoding new information, while different cholinergic conditions accompany other forms of network processing. Such relationships are circuit- and task-dependent rather than evidence that acetylcholine stores memories by itself. Learning also depends on glutamatergic, inhibitory, dopaminergic, and other signaling systems, as well as changes in the strength and structure of synapses.
Cholinergic systems also contribute to sleep–wake regulation. Many basal forebrain and pontine cholinergic neurons show higher activity during wakefulness and rapid-eye-movement sleep than during slow-wave sleep. These patterns helped establish acetylcholine’s role in cortical activation, but cholinergic neurons are neither the sole controllers of arousal nor physiologically uniform. Modern recordings reveal diversity among cells within anatomical groups, including responses related to movement, reinforcement, sensory events, and changes in task engagement.
Degeneration of basal forebrain cholinergic neurons and loss of cholinergic markers occur in Alzheimer’s disease, providing part of the rationale for medicines that inhibit acetylcholinesterase. These drugs can produce symptomatic benefits but do not restore lost neurons or reverse the underlying disease process. Cholinergic abnormalities also occur in other neurological conditions. In Parkinson’s disease, for example, interactions between striatal acetylcholine and dopamine are relevant to motor circuitry, while degeneration of other cholinergic populations can contribute to nonmotor impairments. No single measure of acetylcholine abundance captures all of these circuit-specific changes.
Non-neuronal signaling and comparative biology
Acetylcholine signaling is not confined to nerve terminals. Components of cholinergic systems have been identified in epithelial cells, endothelial cells, keratinocytes, and several immune-cell populations. Depending on the cell type, these components include acetylcholine-synthesizing enzymes, transport mechanisms, receptors, and cholinesterases. In such settings, acetylcholine may act locally on the producing cell or neighboring cells rather than crossing a specialized synaptic cleft. The organization of synthesis and release can differ substantially from the classical neuronal vesicle cycle.
In epithelia, cholinergic signaling has been implicated in regulation of secretion, cell adhesion, proliferation, and barrier properties. Airway epithelial cells, for example, can express elements of a non-neuronal cholinergic system in addition to receiving neural influences. The interpretation of such findings requires attention to experimental context: detecting a receptor or biosynthetic enzyme is not equivalent to demonstrating the magnitude or direction of its normal contribution in an intact organ. Local acetylcholine concentrations and receptor accessibility are often difficult to measure directly.
The relationship between acetylcholine and the immune system has attracted particular interest. Some lymphocyte populations can synthesize acetylcholine, and experimental studies have identified neural–immune circuits in which acetylcholine contributes to regulation of cytokine production. The nicotinic receptor is implicated in several models of inflammatory regulation, including effects involving macrophages. However, receptor signaling in immune cells need not reproduce the rapid electrical responses seen in neurons, and the relevant anatomical pathways differ among organs and experimental preparations.
The expression “cholinergic anti-inflammatory pathway” refers to a body of work linking neural activity, immune-cell signaling, and suppression of certain inflammatory responses. It does not mean that all acetylcholine signaling suppresses inflammation, or that every proposed pathway is a direct cholinergic nerve connection to an immune cell. In extensively studied splenic models, sympathetic signaling and acetylcholine-producing lymphocytes can form parts of an indirect circuit. The details depend on species, stimulus, tissue, and experimental method, making it important to distinguish established cellular observations from broad claims about systemic regulation.
Across animals, the location and importance of cholinergic transmission vary. Acetylcholine receptors and cholinergic signaling are widespread among invertebrates as well as vertebrates, but the vertebrate arrangement is not universal. Many insect neuromuscular junctions use glutamate rather than acetylcholine as their principal excitatory transmitter, while nicotinic receptors are major excitatory receptors in the insect central nervous system. Such differences help explain the selective actions of some insecticides. Reports of acetylcholine in organisms lacking nervous systems further show that the presence of this molecule is not, by itself, evidence of neuronal communication.
Pharmacology, therapeutic uses, and toxic effects
Cholinergic pharmacology distinguishes agents that activate receptors, block receptors, alter acetylcholine release, or inhibit its breakdown. Direct receptor agonists may favor muscarinic or nicotinic receptors, although selectivity is usually relative rather than absolute. Pilocarpine is a muscarinic agonist used in defined clinical settings involving ocular pressure or reduced salivary secretion. Acetylcholine itself has a specialized ophthalmic use for producing rapid pupillary constriction during certain intraocular procedures. Its very short persistence limits its usefulness for sustained effects.
Muscarinic antagonists include atropine, scopolamine, and several drugs designed for more localized or receptor-biased actions. Their effects follow receptor distribution: reduced glandular secretion, altered cardiac rate, relaxation of some smooth muscles, and changes in pupillary function. Inhaled muscarinic antagonists such as ipratropium and tiotropium reduce cholinergic bronchoconstrictor influences in obstructive airway disease. Some antimuscarinic medicines enter the brain readily and can affect cognition, alertness, or memory; others have more restricted central penetration.
Acetylcholinesterase inhibitors increase the persistence of endogenously released acetylcholine. Pyridostigmine is used to improve neuromuscular transmission in myasthenia gravis, while neostigmine has uses that include reversal of certain nondepolarizing neuromuscular blocks. Donepezil, rivastigmine, and galantamine are used for symptomatic treatment in specified dementias. Their effects are not limited to one anatomical site, and peripheral cholinergic actions can accompany central effects. Increasing acetylcholine cannot compensate indefinitely for loss of the cells and circuits required to use it.
Nicotine activates neuronal nicotinic receptors and contributes to tobacco dependence through actions on reward-related circuitry, including modulation of dopamine signaling. Repeated exposure causes both desensitization and changes in receptor abundance, with effects that vary by receptor subtype. Other nicotinic drugs exploit these properties differently: varenicline acts as a partial agonist at -containing receptors and is used in smoking-cessation treatment. Neuromuscular blocking agents target another set of nicotinic receptors, illustrating the importance of receptor-subtype differences in pharmacology.
Organophosphate pesticides and nerve agents can inhibit acetylcholinesterase by covalently modifying its active-site serine. With some compounds, subsequent chemical changes called aging make reactivation increasingly difficult. Severe poisoning causes excessive cholinergic stimulation, potentially including secretions, bronchoconstriction, bradycardia, muscle fasciculations, weakness, seizures, and respiratory failure. Carbamate cholinesterase inhibitors act through a different, generally more readily reversible enzyme modification. The toxicity of these agents reflects both excessive muscarinic signaling and disrupted nicotinic transmission; persistent stimulation can ultimately prevent normal signaling rather than merely amplify it.
Discovery and experimental investigation
Acetylcholine became central to physiology through a sequence of chemical, pharmacological, and electrophysiological discoveries. Adolf von Baeyer synthesized it in 1867, before its transmitter role was recognized. In the early twentieth century, Henry Hallett Dale characterized actions of choline esters and distinguished effects resembling those of muscarine from those resembling nicotine. His 1914 work helped establish a pharmacological framework that later became the division between muscarinic and nicotinic receptors.
In 1921, Otto Loewi reported an experiment using isolated frog hearts. Stimulation of the vagus nerve slowed one heart, and fluid transferred from that preparation could slow a second heart. The result demonstrated the release of a transferable chemical substance rather than an exclusively electrical effect. Loewi called the active material Vagusstoff, or “vagus substance”; subsequent work identified it with acetylcholine. Dale and Loewi shared the 1936 Nobel Prize in Physiology or Medicine for discoveries relating to chemical transmission of nerve impulses.
Evidence for acetylcholine’s role at skeletal neuromuscular junctions developed through studies of transmitter release and muscle responses, including work by Dale, Wilhelm Feldberg, and Marthe Vogt in the 1930s. Later, Bernard Katz and collaborators used intracellular recordings to analyze end-plate potentials. Work by Paul Fatt and Katz identified miniature end-plate potentials, and subsequent experiments supported the quantal nature of transmitter release. These observations helped connect microscopic electrical events with the release of discrete packets of acetylcholine.
Electric organs of rays of the genus Torpedo, which contain abundant specialized cholinergic synapses, became valuable sources of nicotinic receptors and acetylcholinesterase. The snake-venom toxin -bungarotoxin provided a high-affinity probe for muscle-type nicotinic receptors and certain neuronal receptors. Purification, molecular cloning, and structural studies established receptor subunit organization and clarified how ligand binding couples to pore opening. Cryo-electron microscopy has subsequently resolved multiple conformations of cholinergic receptor complexes at high resolution.
Modern studies combine electrophysiology, genetics, imaging, and chemical measurement. Microdialysis coupled with chromatographic analysis can measure extracellular acetylcholine, although rapid degradation and limited sampling resolution complicate interpretation. Enzyme-based electrochemical sensors often detect choline generated from acetylcholine rather than acetylcholine directly. Genetically encoded fluorescent sensors allow recordings of cholinergic signals with improved spatial and temporal resolution, while optogenetic and chemogenetic methods manipulate selected cell populations. Each method samples a different aspect of the system: extracellular concentration, receptor activation, neuronal firing, and behavioral effect are related quantities, but they are not interchangeable.